{
    "clinical_study": {
        "@rank": "102556", 
        "arm_group": {
            "arm_group_label": "Lacosamide", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Study to evaluate the long-term safety and tolerability of Lacosamide (LCM) administered in\n      addition to 1 to \u22643 other Anti-Epileptic Drugs in subjects with epilepsy \u22651 month to \u226418\n      years who currently have uncontrolled partial onset seizures."
        }, 
        "brief_title": "Long-term Extension Study to Investigate Lacosamide as an Add-on Therapy in Children With Partial Onset Seizures", 
        "completion_date": {
            "#text": "January 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Epilepsy", 
        "condition_browse": {
            "mesh_term": [
                "Epilepsy", 
                "Seizures"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary objective of this study is to evaluate the long-term safety and tolerability of\n      LCM administered concomitantly with 1 to \u22643 Anti-Epileptic Drugs (AEDs) in subjects with\n      epilepsy \u22651 month to \u226418 years of age who currently have uncontrolled partial onset\n      seizures.\n\n      The secondary objective is to evaluate the efficacy during long-term exposure to LCM in\n      subjects epilepsy \u22651 month to \u226418 years of age.\n\n      An additional objective is to assess behavior, cognition, quality of life, and development\n      during long-term LCM exposure in pediatric subjects"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved\n             written Informed Consent form (ICF) is signed and dated by the subject or legal\n             representative. The ICF or a specific Assent form, where required, will be signed and\n             dated by minors\n\n          -  Subject has completed the Transition Period of SP0967 or SP0969 (NCT01921205) for the\n             treatment of uncontrolled partial-onset seizures in pediatric epilepsy\n\n          -  Subject is expected to benefit from participation, in the opinion of the investigator\n\n          -  Subject/legal representative is considered reliable and capable of adhering to the\n             protocol (eg, able to understand and complete diaries), visit schedule, and\n             medication intake according to the judgment of the investigator\n\n        Exclusion Criteria:\n\n          -  Subject is receiving any investigational drugs or using any experimental devices in\n             addition to Lacosamide (LCM)\n\n          -  Subject is experiencing an ongoing Serious Adverse Event (SAE)\n\n          -  For subjects \u22656 years of age, subject has a lifetime history of suicide attempt\n             (including an actual attempt, interrupted attempt, or aborted attempt), or has\n             suicidal ideation in the past 6 months as indicated by a positive response (\"Yes\") to\n             either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale\n             (C-SSRS) at Visit 1\n\n          -  Subjects with a major protocol deviation during the primary study (or a deviation\n             related to enrollment criteria for primary study).\n\n          -  Female subject who is pregnant or nursing, and/or a female subject of childbearing\n             potential who is not surgically sterile or does not practice 1 highly effective\n             method of contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "1 Month"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01964560", 
            "org_study_id": "EP0034", 
            "secondary_id": "2012-005012-26"
        }, 
        "intervention": {
            "arm_group_label": "Lacosamide", 
            "description": "Subjects <30 kg (LCM oral solution) 1 mg/ kg - 6 mg/ kg BID (2 mg/kg/ day - 12 mg/ kg/ day)\nSubjects \u226550 kg (LCM tablets): 50 mg - 300 mg BID (100 mg/ day - 600 mg/ day)", 
            "intervention_name": "Lacosamide", 
            "intervention_type": "Drug", 
            "other_name": "VIMPAT"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Lacosamide", 
            "Vimpat", 
            "UCB", 
            "Epilepsy", 
            "Partial Onset Seizures", 
            "Pediatric"
        ], 
        "lastchanged_date": "April 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Charlotte", 
                    "country": "United States", 
                    "state": "North Carolina"
                }, 
                "name": "102"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter, Open-label, Long-term Extension Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Pediatric Subjects With Epilepsy With Partial-Onset Seizures", 
        "overall_official": {
            "affiliation": "+1 877 822 9493", 
            "last_name": "UCB Clinical Trial Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "Argentina: Ministry of Health", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Brazil: Ministry of Health", 
                "Bulgaria: Ministry of Health", 
                "Canada: Health Canada", 
                "Chile: Ministry of Health", 
                "China: Ministry of Health", 
                "Colombia: Ministry of Health and Social Protection", 
                "Czech Republic: State Institute for Drug Control", 
                "Estonia: The State Agency of Medicine", 
                "France: Ministry of Health", 
                "Germany: Ministry of Health", 
                "Greece: Ministry of Health and Welfare", 
                "Hungary: Ministry of Health, Social and Family Affairs", 
                "Israel: Ministry of Health", 
                "Italy: Ministry of Health", 
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "Korea: Food and Drug Administration", 
                "Latvia: State Agency of Medicines", 
                "Lithuania: State Medicine Control Agency - Ministry of Health", 
                "Mexico: Ministry of Health", 
                "Poland: Ministry of Health", 
                "Romania: Ministry of Public Health", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Serbia: Medicines and Medical Devices Agency", 
                "Slovakia: State Institute for Drug Control", 
                "South Africa: Department of Health", 
                "Spain: Ministry of Health", 
                "Sweden: The National Board of Health and Welfare", 
                "Switzerland: Swissmedic", 
                "Taiwan : Food and Drug Administration", 
                "Thailand: Food and Drug Administration", 
                "Turkey: Ministry of Health", 
                "Ukraine: Ministry of Health", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of subjects reporting at least one Treatment-emergent Adverse Event (TEAE) during the study", 
                "safety_issue": "No", 
                "time_frame": "Baseline to the End of Treatment (approximately 96 weeks)"
            }, 
            {
                "measure": "Number of subjects reporting at least one Treatment-emergent Adverse Event (TEAE) leading to discontinuation from the study", 
                "safety_issue": "No", 
                "time_frame": "Baseline to End of Treatment (approximately 96 weeks)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01964560"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of Seizure Free Days at the End of Year 1", 
                "safety_issue": "No", 
                "time_frame": "End of Year 1 of the Study (approximately 52 weeks)"
            }, 
            {
                "measure": "Percentage of Seizure Free Days at the End of Year 2", 
                "safety_issue": "No", 
                "time_frame": "End of Year 2 of the Study (approximately 96 weeks)"
            }
        ], 
        "source": "UCB, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UCB, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}